If You Invested in Marijuana Inc. (MAJI)

MARIJUANA INC (OTCPINK: MAJI), doing business as Exousia Pro, Inc. and described in recent disclosures as "formerly Marijuana, Inc.", is a clinical-stage biotechnology company in the healthcare sector. The company focuses on exosome-based delivery systems and therapies, with applications across oncology, nutraceuticals, cannabinoids, diagnostics, and telehealth-enabled wellness services.

According to multiple company communications, Exousia Pro develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. These engineered exosomes are described as having the potential to selectively target cancer stem cells in cancers such as Glioblastoma multiforme (GBM) and pancreatic cancer, and to support approaches to a broad spectrum of viral infections.

Core biotechnology focus

The company states that its platform enables the custom production of exosomes with enhanced genetic functionality. Its proprietary loading technology can infuse a range of molecules, from drugs to DNA and other small-particle therapeutic materials, into exosomes and related extracellular vesicles. This capability underpins multiple business lines, including oncology therapies, cannabinoid delivery, and nutraceutical products.

Exousia Pro reports that it has filed a provisional patent (#63/877,517) for a method of loading extracellular vesicles. This method is described as a novel process for encapsulating active compounds into exosomes to improve loading efficiency, stability, and delivery of therapeutic agents. The company positions this technology as applicable to pharmaceuticals, nutraceuticals, and cosmetics.

Oncology and orphan drug designation

In its oncology program, Exousia Pro highlights work through its subsidiary Exousia AI on an exosome-based treatment for malignant Glioma (Glioblastoma multiforme, GBM). The company reports that this program has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for GBM. The approach involves exosomes loaded with desired nucleic acids, used in combination with standard anticancer therapy.

The company describes its exosome technology as capable of delivering a wide range of therapeutics, including genetic material, into cancer cells. It emphasizes the goal of addressing diseases with significant unmet medical needs by targeting cancer stem cells, which are characterized as key drivers of recurrence and metastasis.

Exosome-based cannabinoid and edible applications

Exousia Pro has announced development of CBD-loaded exosomes derived from milk. The company reports a proprietary, patent-pending protocol to extract exosomes and load them with Cannabidiol (CBD) material. These specialized exosomes are engineered, according to the company, to remain intact through the digestive tract to support oral drug delivery.

The company has outlined plans for an Institutional Review Board (IRB) study comparing CBD gummies using its CBD-loaded exosomes with standard formulations, with multiple blood draws to measure bioavailability and plasma levels. It characterizes this work as targeting the cannabinoid edible and nutraceutical markets by improving oral delivery efficiency.

Exousia Pro states that all current and planned research and product development activities involve hemp-derived cannabinoids compliant with the 2018 U.S. Farm Bill, containing less than 0.3% Δ9-THC on a dry-weight basis, and that it does not engage in business involving marijuana or Schedule I controlled substances under U.S. federal law.

Nutraceuticals and Maxasome™

The company has announced the launch of Maxasome™, described as its flagship nutraceutical. Maxasome™ is characterized as an all-natural, biologically active exosomal supplement derived from Exosome-Like Nanoparticles (ELNs) extracted from Yellow Oyster Mushroom (Pleurotus citrinopileatus). The product is presented as a multi-modal cytoprotective agent aimed at cellular defense and health span.

According to Exousia Pro, Maxasome™ uses 100% exosomal delivery, encapsulating its bioactive payload within naturally derived ELNs to protect molecules in the digestive system and support systemic uptake. The company states that the formulation delivers a spectrum of molecules such as Ergothioneine, Beta-glucans, Terpenoids, Phenolic Compounds, and Vitamin D2, and that it is intended to support anti-aging, cellular defense, and skin and tissue regeneration.

The company indicates that Maxasome™ can be administered as a sublingual tincture, nasal inhalant, or enteric-coated capsules, and that it plans to offer the product on a monthly subscription basis as part of a recurring revenue strategy in the longevity and wellness market.

Diagnostics and cancer screening

Through an exclusive licensing agreement with the University of Central Florida (UCF), Exousia Pro reports that its wholly owned subsidiary, Exousia Pro Holding Management, LLC (EPHM), has obtained rights to UCF-developed patented and patent-pending intellectual property related to exosome-based cancer diagnostics and therapies.

The licensed portfolio includes a U.S. patent (US011193174B2) covering the use of Exosomal NANOG DNA as a diagnostic cancer marker. The company describes plans to develop a NANOG DNA cancer screening test as a non-invasive, saliva-based multi-cancer screening tool. The test is characterized as using PCR processing on a small saliva sample, with design goals that include universal screening, high sensitivity and specificity, and minimal influence from medications or co-existing health conditions.

Exousia Pro states that it intends to form a subsidiary, Exousia Health, to manage commercialization of the NANOG DNA cancer screening test under a sub-license from EPHM. It also indicates that a majority-owned subsidiary, LAMY (to become Exousia Bio, Inc., OTCID: LMMY), will receive a sub-license for cancer-therapy applications.

Telehealth and Exousia Health division

The company has announced plans to expand into telehealth via a new division, Exousia Health. It reports agreements and letters of intent to acquire telehealth businesses that will form the foundation of this division. According to Exousia Pro, these telehealth assets are expected to provide an existing patient base and recurring monthly revenue.

The company describes Exousia Health as intended to support telehealth networks and clinics that market anti-aging and regenerative compounds, including GLP-1 and Testosterone therapies, and to serve as a channel for products such as Maxasome™ and the NANOG DNA cancer screening test. It has also referenced plans for a compounding pharmacy within Exousia Health to process prescriptions from its telehealth doctors.

In a later announcement, Exousia Pro describes an executed Letter of Intent to acquire a high-growth telehealth organization to operate under Exousia Health, Inc. The company states that this platform includes a contract designating it as the exclusive supplier of Testosterone across a network of clinics, and that it expects this arrangement to support sales of its nutraceutical and diagnostic products.

Corporate structure, subsidiaries, and strategic realignment

Exousia Pro has outlined a multi-division structure that includes:

• Exousia AI, Inc. – focused on exosome-based cancer therapies, including GBM treatment and associated intellectual property.
• Exousia Health – focused on telehealth, nutraceuticals, diagnostics, and related revenue streams.
• Exousia Pro Holding Management, LLC (EPHM) – holding exclusive licenses from UCF for exosome-based diagnostic and therapeutic technologies.
• LAMY / Exousia Bio, Inc. (OTCID: LMMY) – a majority-owned SEC-reporting company intended to advance certain exosome-based cancer therapies under sub-license.

The company reports that it has completed an all-stock transaction in which it acquired a controlling interest in LAMY (OTCID: LMMY) by exchanging its subsidiary Exousia AI, Inc. Exousia Pro states that it received approximately 51% of LMMY restricted common stock, making MAJI the controlling shareholder of LMMY. It describes this as part of a strategic realignment intended to establish core divisions as independent, publicly traded entities.

Exousia Pro indicates that it has entered into a licensing agreement with LMMY, providing for annual licensing fees and ongoing royalties based on the commercial success of technology exploited by LMMY through Exousia AI. It characterizes its equity in LMMY as a non-dilutive asset that can be used to support MAJI’s own corporate objectives.

Legal and corporate governance actions

The company has reported legal proceedings involving a former sole officer and director and related shareholders. Following a court hearing, Exousia Pro states that a standstill order was executed on shares held by the former CEO and that rescission agreements were put in place to address additional shares. The company presents these steps as measures to protect shareholder interests and to support its focus on exosome therapies and related business initiatives.

Geographic and market orientation

Exousia Pro’s news releases reference operations and corporate activities based in Orlando, Florida. The company positions itself within the healthcare sector as a clinical-stage biotechnology company with exposure to oncology, cannabinoid delivery, nutraceuticals, diagnostics, cosmetics, and telehealth markets. It frequently highlights the potential relevance of its technologies to large global markets in pharmaceuticals, nutraceuticals, cosmetics, and telehealth.

Business model and revenue themes

Based on its public statements, Exousia Pro’s business model centers on:

• Developing and licensing exosome-based therapeutic platforms, particularly in oncology.
• Commercializing exosome-enabled nutraceuticals, such as Maxasome™, often using subscription models.
• Offering exosome loading processes to third-party manufacturers, including CBD manufacturers, through reseller networks.
• Building telehealth and diagnostic channels via Exousia Health to distribute nutraceutical and cancer screening products.
• Structuring licensing and royalty agreements with affiliated public entities such as LMMY.

The company’s communications emphasize the use of proprietary exosome manufacturing and loading technologies as the common foundation for these activities.